High doses of mother's lymphocyte infusion to treat EBV-positive T-cell lymphoproliferative disorders in childhood

Wang, Qian; Liu, Hongxing; Zhang, Xian; Liu, Qian; Xing, Yanping; Zhou, Xiaoge; Tong, Chunrong; Zhu, Ping

doi:10.1182/blood-2010-01-262311

Cited by 18 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are similar to findings by Meeh et al who demonstrated that Vδ1+ T cells respond to acute leukemia [28]. However, further characterization of the biological functions of the Vδ4+ T cell clone is needed; the reactive T cell clone may be amplified and used to study adoptive anti-leukemia immunotherapy, moreover, the TCR Vδ4 and its pattner Vγ gene could be used for transfer and the modification of normal T cells for identification their anti-leukemia effect [6,14,31,32]. …”

Section: Resultssupporting

confidence: 54%

“…Moreover, TCR rearrangements also provide different recombination breakpoints that lead to the creation of fusion genes [12]. TCR rearrangement analysis may be used to determine T-ALL immunogenetic characteristics, and TCR rearrangements may be characterized by leukemia antigen-reactive T cell clones, which are thought to be specific to anti-leukemic cytotoxic T cells [13,14]. …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The evolution of malignant and reactive γδ + T cell clones in a relapse T-ALL case after allogeneic stem cell transplantation

et al. 2013

View full text Add to dashboard Cite

BackgroundTo improve the outcome of patients with T-cell acute lymphoblastic leukemia (T-ALL), characterization of the biological features of T-ALL blast cells and the immune status of patients with T-ALL is needed to identify specific therapeutic strategies.FindingsUsing a novel approach based on the combination of fine-tiling comparative genomic hybridization (FT-CGH) and ligation-mediated PCR (LM-PCR), we molecularly identified a malignant γδ + T cell clone with a Vδ5Dδ2Jδ1 rearrangement that was paired with a T cell receptor (TCR) VγI and comprised a Vγ1Vδ5 T cell clone in a relapse T-ALL patient. This malignant Vδ5 T cell clone disappeared after chemotherapy, but the clone was detected again when disease relapsed post allogeneic hematopoietic stem cell transplantation (allo-HSCT) at 100 weeks. Using PCR and GeneScan analyses, the distribution and clonality of the TCR Vγ and Vδ subfamilies were examined before and after allo-HSCT in the patient. A reactive T cell clone with a Vδ4Dδ3Jδ1 rearrangement was identified in all samples taken at different time points (i.e., 4, 8, 68, 100 and 108 weeks after allo-HSCT). The expression of this Vδ4+ T cell clone was higher in the patient during complete remission (CR) post allo-HSCT and at disease relapse.ConclusionsThis study established a sensitive methodology to detect T cell subclones, which may be used to monitor minimal residual disease and immune reconstitution.

show abstract

Section: Resultssupporting

confidence: 54%

Section: Resultsmentioning

confidence: 99%

The evolution of malignant and reactive γδ + T cell clones in a relapse T-ALL case after allogeneic stem cell transplantation

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Probability of survival after transplantation was higher in patients transplanted at a younger age with inactive disease at the time of transplant. These diseases arise often in young children, and the possibility to treat them with high doses of mother's lymphocyte infusion was studied in 5 patients, with complete response in 3 and partial response in 2 (Wang et al 2010). The in vitro killing effect of a combination of valproic acid and bortezomib on the T/NK proliferating cells was recently described and could be an option for future treatment (Iwata et al 2012).…”

Section: T/nk Cell Ebv-associated Lymphoproliferative Diseases In Nonmentioning

confidence: 99%

Prevention and Treatment for Epstein–Barr Virus Infection and Related Cancers

Smets

Sokal

2013

Viruses and Human Cancer

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) was the first herpes virus described as being oncogenic in humans. EBV infection is implicated in post-transplant lymphoproliferative diseases (PTLD) and several other cancers in non-immunocompromised patients, with more than 200,000 new cases per year. While prevention of PTLD is improving, mainly based on EBV monitoring and preemptive tapering of immunosuppression, early diagnosis remains the best current option for the other malignancies. Significant progress has been achieved in treatment, with decreased mortality and morbidity, but some challenges are still to face, especially for the more aggressive diseases. Possible prevention by EBV vaccination would be a more global approach of this public health problem, but further active research is needed before this goal could be reached.

show abstract

“…One alternative is the use of haploidentical maternal donor lymphocytes which make use of feto-maternal tolerance to reduce the potential for GvHD (46). Another strategy to reconstitute EBVspecific T-cell immunity is via transfer of in vitro generated autologous and allogeneic EBV-specific CTL.…”

Section: Adoptive Immunotherapymentioning

confidence: 99%

Epstein–Barr Virus-Related Post-Transplant Lymphoproliferative Disorders: Pathogenetic Insights for Targeted Therapy

Nourse

Jones

Gandhi

2011

American Journal of Transplantation

124

View full text Add to dashboard Cite

Post-transplant lymphoproliferative disorder (PTLD) is a spectrum of major, life-threatening lymphoproliferative diseases occurring in the post-transplant setting. The majority of PTLD is of B-cell origin and is associated with several risk factors, the most significant being Epstein-Barr virus (EBV) infection. EBV's in vitro transforming abilities, distinctive latency, clonality within the malignant cells and response to targeted therapies implicate a critical role in the biology of PTLD. This minireview focuses on EBV-related PTLD pathogenesis, in particular the interplay between aspects of the EBV life cycle and latency with nonviral factors resulting in the wide spectrum of histology and clinical presentations encountered in PTLD. With the increased prevalence of transplantation a rise in the incidence of PTLD may be expected. Therefore the importance of laboratory and animal models in the understanding of PTLD and the development of novel therapeutic approaches is discussed.

show abstract

High doses of mother's lymphocyte infusion to treat EBV-positive T-cell lymphoproliferative disorders in childhood

Cited by 18 publications

References 34 publications

The evolution of malignant and reactive γδ + T cell clones in a relapse T-ALL case after allogeneic stem cell transplantation

The evolution of malignant and reactive γδ + T cell clones in a relapse T-ALL case after allogeneic stem cell transplantation

Prevention and Treatment for Epstein–Barr Virus Infection and Related Cancers

Epstein–Barr Virus-Related Post-Transplant Lymphoproliferative Disorders: Pathogenetic Insights for Targeted Therapy

Contact Info

Product

Resources

About